Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results

G Mathé; J L Misset; R Plagne; P Reizenstein; D Belpomme; B Le Mevel; J Guerrin; P Fumoleau; R Metz; M Delgado

Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results

Drugs Exp Clin Res. 1986;12(1-3):143-5.

Authors

G Mathé, J L Misset, R Plagne, P Reizenstein, D Belpomme, B Le Mevel, J Guerrin, P Fumoleau, R Metz, M Delgado, et al.

PMID: 3525068

Abstract

Adjuvant treatment of breast cancer with AVCF gave significantly longer disease-free survival than CMF in the group of patients taken as a whole, in the subgroup with lymph node involvement and in the premenopausal subgroup. No significant difference was found regarding overall survival.

Publication types

Clinical Trial
Comparative Study
Controlled Clinical Trial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / radiotherapy
Clinical Trials as Topic
Combined Modality Therapy
Cyclophosphamide / administration & dosage
Doxorubicin / administration & dosage
Female
Fluorouracil / administration & dosage
Humans
Lymphatic Metastasis
Menopause
Methotrexate / administration & dosage
Random Allocation
Vincristine / administration & dosage

Substances

Vincristine
Doxorubicin
Cyclophosphamide
Fluorouracil
Methotrexate

Supplementary concepts

AVCF protocol
CMF regimen